news
Could medicinal cannabis be the answer to the opioid crisis?
New data from the UK shows 86 percent of pain patients found medicinal cannabis more effective than any other medication, including opioids.
List view / Grid view
cannabidiol (CBD)
article
Ten recommendations to foster the UK’s medicinal cannabis market
In this article, EPR summarises the list of 10 recommendations for the UK Government, published by experts in the medicinal cannabis industry, to ensure the UK capitalises on the opportunities afforded by the market.
article
Why it’s high time for psychedelic drug development
Here, Dr Matthew McMurray and Dr J Andrew Jones of Miami University explain why psychedelic drugs are attracting R&D as potential treatments for neuropsychiatric and degenerative disorders and how their discovery of an in vivo production technique could enable further advancement.
news
FDA sends warning to companies selling unapproved CBD products
The warning letters were issued to two companies illegally selling over-the-counter cannabidiol (CBD) products for pain relief.
article
Carving out a slice of the European medical cannabis market
The European medical cannabis market lacks a common regulatory framework; Peter Kohut charts a route through the complexity and highlights opportunities for the taking.
article
Cannabinoid series: medicinal cannabis and Brexit
Sarah Ellson from Fieldfisher spoke with European Pharmaceutical Review to discuss the position of medicinal cannabis in the UK and the impacts of Brexit.
article
Cannabinoid series: developing a synthetic CBD tablet
Aubrey Dan explains how EmpowerPharm developed its synthetic CBD tablet and why a novel formulation could help combat a range of indications.
article
Cannabinoid series: growing and extracting APIs
Michael Sassano from Somai Pharmaceuticals and Solaris Farms discusses the US and European markets for growing and extracting cannabinoids for the pharmaceutical industry.
article
A novel cannabinoid formulation for glioblastoma treatment
Earlier this year, MGC Pharmaceuticals, in collaboration with the Slovenian National Institute of Biology (NIB) and the Neurosurgery Department at the University Medical Centre in Ljubljana, Slovenia, announced successful research results for their novel cannabinoid formulation, which has been developed for the treatment of glioblastoma. This article highlights the key…
article
Cannabinoid series: a CBD cocrystal for the treatment of PTSD
European Pharmaceutical Review spoke with Dr Andy Yates to discuss Artelo Bioscience’s new CBD and TMP cocrystal, with the potential to treat PTSD.
news
Report calls for development of new cannabis testing technologies
According to research, the rise in demand for high-quality cannabis will also drive growth in the cannabis testing market, where new technologies are needed to overcome current limitations.
news
CBD could reduce behavioural problems in children with intellectual disability
A new study has shown that in children and adolescents with an intellectual disability, cannabidiol (CBD) reduced severe behavioural problems.
article
Latest innovations in child-resistant pharmaceutical packaging
The problem of children accessing medication at home is growing and the UK’s National Health Service (NHS) claims the most common form of poisoning1 in the UK is from medication, with children under five being most at risk. While parents have a role to play in the home by keeping…
news
FDA sends two warnings to companies selling unapproved CBD products
Two companies selling unapproved cannabidiol (CBD) products including for the treatment of opioid addiction, have been handed warning letters from the FDA.
news
Handheld Raman spectrometer developed to analyse THC levels in cannabis plants
Researchers have modified a portable Raman spectrometer that can determine the level of THC in cannabis plants, which they say could be used by farmers wishing to grow hemp.